Corey M Gill1, Megan R D'Andrea2, Shannon Tomita3, Jessa Suhner3, Melissa Umphlett4, Konstantin Zakashansky3, Stephanie V Blank3, Nadejda Tsankova4, Raj K Shrivastava2, Mary Fowkes4, Valentin Kolev3. 1. Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA. corey.gill@icahn.mssm.edu. 2. Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA. 3. Obstetrics, Gynecology, and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA. 4. Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
Abstract
INTRODUCTION: The density and distribution of the tumor immune microenvironment associated with brain metastases (BM) from gynecologic malignancies are unknown and have not been previously reported. We sought to describe the clinical features of a cohort of patients with BM from gynecologic malignancies and to characterize the tumor immune microenvironment from available archival surgical specimens. METHODS: We performed a retrospective review of electronic medical records from 2002 to 2018 for patients with BM from gynecologic malignancies. Data on patient characteristics, treatment regimens, and clinical outcomes were procured. CD4, CD8, CD45RO, CD68, CD163, and FOXP3 immunohistochemistry were evaluated from available archival surgical specimens from primary disease site and neurosurgical resection. RESULTS: A cohort of 44 patients with BM from gynecologic malignancies was identified, 21 (47.7%) endometrial primaries and 23 (52.3%) ovarian primaries. Tumor-infiltrating lymphocytes (TILs) and tumor-associated macrophages (TAMs) were evaluated in 13 primary cases and 15 BM cases. For the 13 primary cases, CD4+ TILs were evident in 76.9% of cases, CD8+ in 92.3%, CD45RO+ in 92.3%, and FOXP3+ in 46.2%, as well as CD68+ TAMs in 100% and CD163+ in 100%. For the 15 BM cases, CD4+ TILs were evident in 60.0% of cases, CD8+ in 93.3%, CD45RO+ in 73.3%, and FOXP3+ in 35.7%, as well as CD68+ TAMs in 86.7% and CD163+ in 100%. CONCLUSION: An active tumor immune microenvironment is present with similar distribution in the primary disease site and BM from patients with gynecologic malignancies.
INTRODUCTION: The density and distribution of the tumor immune microenvironment associated with brain metastases (BM) from gynecologic malignancies are unknown and have not been previously reported. We sought to describe the clinical features of a cohort of patients with BM from gynecologic malignancies and to characterize the tumor immune microenvironment from available archival surgical specimens. METHODS: We performed a retrospective review of electronic medical records from 2002 to 2018 for patients with BM from gynecologic malignancies. Data on patient characteristics, treatment regimens, and clinical outcomes were procured. CD4, CD8, CD45RO, CD68, CD163, and FOXP3 immunohistochemistry were evaluated from available archival surgical specimens from primary disease site and neurosurgical resection. RESULTS: A cohort of 44 patients with BM from gynecologic malignancies was identified, 21 (47.7%) endometrial primaries and 23 (52.3%) ovarian primaries. Tumor-infiltrating lymphocytes (TILs) and tumor-associated macrophages (TAMs) were evaluated in 13 primary cases and 15 BM cases. For the 13 primary cases, CD4+ TILs were evident in 76.9% of cases, CD8+ in 92.3%, CD45RO+ in 92.3%, and FOXP3+ in 46.2%, as well as CD68+ TAMs in 100% and CD163+ in 100%. For the 15 BM cases, CD4+ TILs were evident in 60.0% of cases, CD8+ in 93.3%, CD45RO+ in 73.3%, and FOXP3+ in 35.7%, as well as CD68+ TAMs in 86.7% and CD163+ in 100%. CONCLUSION: An active tumor immune microenvironment is present with similar distribution in the primary disease site and BM from patients with gynecologic malignancies.
Authors: Janis M Taube; Alison Klein; Julie R Brahmer; Haiying Xu; Xiaoyu Pan; Jung H Kim; Lieping Chen; Drew M Pardoll; Suzanne L Topalian; Robert A Anders Journal: Clin Cancer Res Date: 2014-04-08 Impact factor: 12.531
Authors: Stefano Uccella; Jonathan M Morris; Francesco Multinu; William A Cliby; Karl C Podratz; Bobbie S Gostout; Sean C Dowdy; Fabio Ghezzi; Peter B Makdisi; Gary L Keeney; Michael J Link; Andrea Mariani Journal: Gynecol Oncol Date: 2016-04-26 Impact factor: 5.482
Authors: Lilian T Gien; Janice S Kwon; David P D'Souza; John S Radwan; J Alex Hammond; Akira K Sugimoto; Mark S Carey Journal: Gynecol Oncol Date: 2004-05 Impact factor: 5.482
Authors: Justin C Chura; Robin Marushin; Anders Boyd; Rahel Ghebre; Melissa A Geller; Peter A Argenta Journal: Gynecol Oncol Date: 2007-06-22 Impact factor: 5.482
Authors: Laura M Divine; Nora T Kizer; Andrea R Hagemann; Meredith E Pittman; Ling Chen; Matthew A Powell; David G Mutch; Janet S Rader; Premal H Thaker Journal: Gynecol Oncol Date: 2016-05-08 Impact factor: 5.482